Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyrolae herba, known in Traditional Chinese Medicine (TCM) as Lu Xian Cao, is a botanical preparation derived from the dried whole plant of *Pyrola calliantha* H. Andres or *Pyrola decorata* H. Andres. It is a chemically complex herbal medicine containing over 70 identified compounds, including flavonoids (such as hyperoside), phenolic glycosides, quinones (notably chimaphilin), and terpenoids (such as ursolic acid). The herb is traditionally valued for its anti-inflammatory, antioxidant, and osteoprotective properties. In clinical practice, particularly within China, it is used to treat a wide range of conditions including rheumatic and rheumatoid arthritis, bone hyperplasia, sciatica, and chronic bronchitis. Research suggests it may also have applications in managing hypertension, coronary heart disease, and certain tumors by modulating multiple biological pathways rather than acting on a single molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyrolae herba.